Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 68
Filter
1.
South Asian J Cancer ; 7(3): 167-170, 2018.
Article in English | MEDLINE | ID: mdl-30112331

ABSTRACT

BACKGROUND: Indo-Gangetic basin is known to have higher incidence of gallbladder cancer. Proximity to River Ganga and high heavy metal in soil exposure have been postulated as risk factors. AIM: This study aims to evaluate the geographical pattern of gallbladder cancer from consecutive patient database enrolled in hospital-based cancer registry (HBCR). OBJECTIVES: To evaluate demographic profile and districtwise/zonewise dispersion of gallbladder cancer cases registered in HBCR from year 2014 to 2016. To evaluate association of carcinoma gallbladder (CaGB) due to proximity of Ganges, districts of high soil arsenic levels and referral bias. MATERIALS AND METHODS: Demographic profile and district-based location of individual consecutive gallbladder cancer patient registered in Regional Cancer Centre from the year 2014 till 2016 were analyzed. Population data from 2011 census and arsenic soil content data from central groundwater body were obtained. Frequency distribution, cross tabulation, and odds ratio were used to analyze risk of CaGB across population subsets in Bihar. RESULTS: A total of 1291 consecutive patients of CaGB were registered from 2014 to 2016. Median age at diagnosis was 55 years (range 18-95 years). Male to female ratio was 0.6. Patna (16%) followed by Vaishali (5.8%), Sitamarhi (5%), Madhubani (4.7%), Gaya (4%), and Samastipur (4%) had highest cases. Districts along main central River Ganga (n = 12) and those exposed to high arsenic soil content (n = 15) had higher odds ratio for CaGB, 1.72 (95% confidence interval [CI]: 1.54-1.91, P = 0.001), and 1.45 (95% CI: 1.30-1.62, P = 0.001), respectively. Districts within 100 km radius of our institute had higher gallbladder cancer cases, odds ratio 1.81 (95% CI: 1.62-2.03, P = 0.001), suggesting significant referral bias predominantly contributed by cases registered under Patna and Vaishali districts. CONCLUSION: CaGB is major public health problem in Bihar. Exposure to high soil arsenic levels and proximity to River Ganga are strongly associated with gallbladder cancer. Systematic population-based longitudinal studies are needed to explore above hypothesis.

2.
Biomed Res Int ; 2015: 745062, 2015.
Article in English | MEDLINE | ID: mdl-26090441

ABSTRACT

Post-kala-azar dermal leishmaniasis (PKDL) is an important factor in kala-azar transmission; hence its early detection and assessment of effective treatment is very important for disease control. In present study on 60 PKDL cases presented with macular, mixed papulonodular, or erythematous lesions, Leishmania parasites were demonstrated microscopically in 91% of papulonodular and 40% of macular lesions. Cellular infiltrates in skin biopsy imprint smears from lesions were mononuclear cells, 25-300/OIF (oil immersion field), predominantly histiocytes with vacuolation, many lymphocytes, some plasma cells, and Leishmania amastigotes 0-20/OIF. Cases with no demonstrable parasites were diagnosed on the basis of past history of VL, lesion's distribution, cytopathological changes, and positive DAT (86.83%). Following antileishmanial treatment with SAG, papulonodular forms of PKDL lesions disappeared clinically but microscopically the mononuclear cells (20-200/OIF) persisted in the dermal lesions. Response observed in macular PKDL lesions was poor which persisted both clinically and cytopathologically. Follow-up of PKDL will assess the effectivity of treatment as either disappearance of lesions or any relapse. Studies on involvement of immunological factors, that is, certain cytokines (IL-10, TGF-ß, etc.) and chemokines (macrophage inflammatory protein, MIP 1-α, etc.) in PKDL, may provide insight for any role in the treatment response.


Subject(s)
Leishmaniasis, Cutaneous/physiopathology , Leishmaniasis, Visceral/immunology , Leishmaniasis, Visceral/physiopathology , Adolescent , Adult , Child , Female , Humans , Interleukin-10/immunology , Leishmania donovani/immunology , Leishmania donovani/pathogenicity , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Cutaneous/transmission , Leishmaniasis, Visceral/transmission , Male , Middle Aged , Transforming Growth Factor beta/immunology , Treatment Outcome
4.
PLoS Negl Trop Dis ; 8(1): e2611, 2014.
Article in English | MEDLINE | ID: mdl-24392171

ABSTRACT

BACKGROUND: The skin disorder Post Kala-Azar Dermal Leishmaniasis (PKDL) occurs in up to 10% of patients treated for visceral leishmaniasis (VL) in India. The pathogenesis of PKDL is not yet fully understood. Cases have been reported in India following therapy with most available treatments, but rarely in those treated with liposomal amphotericin B (Ambisome). Between July 2007 and August 2012 with the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) supported a VL treatment programme in Bihar, India-an area highly endemic for Leishmania donovani-in which 8749 patients received 20 mg/kg intravenous Ambisome as first-line treatment. This study describes the characteristics of patients who returned to the MSF supported treatment programme with PKDL. METHODS AND PRINCIPAL FINDINGS: Over a 5-year period, Ambisome was administered to 8749 patients with laboratory-confirmed VL (clinical signs, rK39 positive, with/without parasite confirmation) in four intravenous doses of 5 mg/kg to a total of 20 mg/kg, with a high initial-cure rate (99.3%) and low default rate (0.3%). All patients received health education highlighting the possibility and symptoms of developing PKDL, and advice to return to the MSF programme if these symptoms developed. This is an observational retrospective cohort study of the programme outcomes. Of the 8311 patients completing treatment for their first episode of VL, 24 (0.3%) returned passively to the programme complaining of symptoms subsequently confirmed as PKDL, diagnosed from clinical history, appearance consistent with PKDL, and slit-skin smear examination. Of the 24 patients, 89% had macular lesions, with a median time (interquartile range) to development of 1.2 (0.8-2.2) years following treatment. Comparison of the demographic and clinical characteristics of the VL patients treated with Ambisome who later developed PKDL, with those of the remaining cohort did not identify any significant risk factors for PKDL. However, the time to developing PKDL was significantly shorter with Ambisome than in a subset of patients presenting to the programme with PKDL following previous sodium stibogluconate treatment for VL. CONCLUSIONS: In this large cohort of patients with VL in Bihar who were treated with 20 mg/kg Ambisome, PKDL following treatment appears to be infrequent with no predictive risk factors. The shorter median time to developing symptoms of PKDL compared with that after conventional VL treatments should be taken into account when counseling patients treated with regimens including Ambisome.


Subject(s)
Amphotericin B/administration & dosage , Antiprotozoal Agents/administration & dosage , Leishmania donovani/isolation & purification , Leishmaniasis, Cutaneous/diagnosis , Leishmaniasis, Visceral/drug therapy , Adolescent , Adult , Child , Child, Preschool , Cohort Studies , Female , Humans , India , Infant , Male , Middle Aged , Recurrence , Retrospective Studies , Treatment Failure , Young Adult
5.
J Clin Microbiol ; 51(12): 4217-9, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24068017

ABSTRACT

Diagnosis of post-kala-azar dermal leishmaniasis (PKDL), particularly the macular form, is difficult when based on microscopy. This study compared the results of nested PCR (91.9% positive samples) with imprint smear microscopy (70.9% positive samples) for 62 PKDL samples. We found that nested PCR, which indicated 87.5% positivity for the macular lesions, compared to 41.6% positivity by imprint smear microscopy, is an efficient method for early diagnosis of PKDL.


Subject(s)
Clinical Laboratory Techniques/methods , Diagnostic Tests, Routine/methods , Leishmaniasis, Cutaneous/diagnosis , Microscopy/methods , Parasitology/methods , Polymerase Chain Reaction/methods , Biopsy , Humans , Skin/pathology
6.
Trans R Soc Trop Med Hyg ; 106(12): 770-2, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23102868

ABSTRACT

In India, the eastern state of Bihar is particularly badly affected by visceral leishmaniasis (VL). It was in Bihar in the 1980s that the first clear signs of resistance to pentavalent antimonials, which had then been the standard antileishmanial treatment for several decades, were observed. New drugs and new formulations of old drugs have since been developed for the treatment of VL. However, despite some initial signs of benefit after each major revision in the method of treatment of VL in India, the VL-related case fatality rates recorded in India since the 1970s show no clear evidence of long-term success. In fact, the most recent data indicate that such rates have stabilised or even increased, probably because of the continued usage of sodium stibogluconate in northern Bihar.


Subject(s)
Antimony Sodium Gluconate/therapeutic use , Antiprotozoal Agents/therapeutic use , Drug Resistance , Leishmaniasis, Visceral/mortality , Mortality/trends , Humans , India/epidemiology , Leishmaniasis, Visceral/drug therapy , Leishmaniasis, Visceral/prevention & control , Treatment Failure
7.
Int J Clin Pharm ; 33(5): 726-9, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21833710

ABSTRACT

CASE: We report a 32-year old relapse case of Visceral leishmaniasis, treated with Paromomycin who belonged from a endemic zone of Bihar state, India. After confirmation, he was treated with Amphotericin B, followed by Liposomal Amphotericin B in full course and even in higher dose. But after each therapy, the patient either did not responded or relapsed after treatment. Ultimately, the patient was successfully treated with combination therapy of Liposomal amphotericin B and Miltefosine without any relapse. CONCLUSION: The multi-drug unresponsive Visceral leishmaniasis cases could pose a major threat to treatment strategy in the elimination program. In such situation, combination therapy seems to be a better approach that needs to be explored.


Subject(s)
Amphotericin B/therapeutic use , Antiprotozoal Agents/therapeutic use , Drug Resistance, Multiple/drug effects , Drug Therapy, Combination/methods , Leishmaniasis, Visceral/drug therapy , Phosphorylcholine/analogs & derivatives , Adult , Amphotericin B/administration & dosage , Antiprotozoal Agents/administration & dosage , Humans , Male , Phosphorylcholine/administration & dosage , Phosphorylcholine/therapeutic use , Recurrence
8.
Ann Card Anaesth ; 14(2): 97-103, 2011.
Article in English | MEDLINE | ID: mdl-21636929

ABSTRACT

Renal artery disease is the most common cause for surgically curable form of hypertension. In a small subset of patients with severe aortic disease where the aorta is not suitable for endovascular technique and to provide an arterial inflow, an extra-anatomic renal bypass surgery (EARBS) is an option. Anesthetic management of such procedures has not been described so far in the literature. We retrospectively analyzed the anesthetic techniques used in all patients who underwent EARBS between February 1998 and June 2008 at this institute. We also further analyzed data concerning blood pressure (BP) control and renal function response following surgery as outcome variable measures. A total of 11 patients underwent EARBS during this period. Five received oral clonidine with premedication. During laryngoscopy, esmolol was used in 4 patients, while lignocaine was used in remaining 7 patients. Of 11 patients, 7 showed significant hemodynamic response to laryngoscopy and intubation; among these, one had oral clonidine with premedicant, and 6 received lignocaine just before laryngoscopy. Intravenous vasodilators were used to maintain target BP within 20% of baseline during perioperative period. All patients received renal protective measures. During follow-up, 10% were considered cured, 70% had improved BP response, while 20% failed to show improvement in BP response. Renal functions improved in 54.5%, remain unchanged in 36.5%, and worsened in 9% of patients. Use of clonidine during premedication and esmolol before laryngoscopy were beneficial in attenuating hemodynamic response to laryngoscopy, while use of vasodilators to maintain target BP within 20% of baseline, and routine use of renal protective measures appear to be promising in patients undergoing EARBS.


Subject(s)
Anesthesia, General , Hypertension, Renovascular/surgery , Kidney/surgery , Vascular Surgical Procedures , Adrenergic alpha-Agonists , Adrenergic beta-Antagonists/therapeutic use , Adult , Blood Pressure/physiology , Clonidine , Female , Humans , Intubation, Intratracheal/adverse effects , Intubation, Intratracheal/methods , Kidney/physiopathology , Kidney Function Tests , Male , Middle Aged , Monitoring, Intraoperative/methods , Postoperative Complications/mortality , Postoperative Complications/physiopathology , Postoperative Complications/therapy , Preanesthetic Medication , Preoperative Care , Propanolamines/therapeutic use , Retrospective Studies , Treatment Outcome , Urodynamics/physiology , Vascular Grafting , Vascular Surgical Procedures/mortality
9.
Lancet Infect Dis ; 11(4): 322-5, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21453873

ABSTRACT

The world's burden of infectious diseases can be substantially reduced by more-effective use of existing interventions. Advances in case detection, diagnosis, and treatment strategies have made it possible to consider the elimination of visceral leishmaniasis in the Indian subcontinent. The priority must now be to effectively implement existing interventions at the community level by actively finding cases in endemic villages and treating them with single-dose liposomal amphotericin B at primary-health-care centres. Once the elimination target of one case per 10,000 population has been reached, combination therapies involving miltefosine and paromomycin can be introduced to ensure long-term availability of several drugs for visceral leishmaniasis and to protect against resistance.


Subject(s)
Antiprotozoal Agents/administration & dosage , Communicable Disease Control/methods , Leishmaniasis, Visceral/epidemiology , Leishmaniasis, Visceral/prevention & control , Amphotericin B/administration & dosage , Drug Therapy, Combination , Humans , Leishmaniasis, Visceral/diagnosis , Leishmaniasis, Visceral/drug therapy , Paromomycin/administration & dosage , Phosphorylcholine/administration & dosage , Phosphorylcholine/analogs & derivatives
10.
Lancet ; 377(9764): 477-86, 2011 Feb 05.
Article in English | MEDLINE | ID: mdl-21255828

ABSTRACT

BACKGROUND: Improved treatment approaches are needed for visceral leishmaniasis. We assessed the efficacy and safety of three potential short-course combination treatments compared with the standard monotherapy in India. METHODS: Standard treatment (1 mg/kg amphotericin B infusion on alternate days for 30 days, total dose 15 mg/kg) was compared with three drug combinations (single injection of 5 mg/kg liposomal amphotericin B and 7-day 50 mg oral miltefosine or single 10-day 11 mg/kg intramuscular paromomycin; or 10 days each of miltefosine and paromomycin) in an open-label, parallel-group, non-inferiority, randomised controlled trial in two hospital sites in Bihar, India. Patients aged 5-60 years with parasitologically confirmed visceral leishmaniasis were randomly assigned one of the four treatments by the trial statistician by use of a computer-generated list. Clinical assessments were done at the end of treatment (15 days on combination treatment; 31 days for standard treatment) and after 45 days and 6 months. The primary endpoint was definitive cure (defined as no sign or symptom of visceral leishmaniasis and parasitologically cured to the last follow-up). Analyses were done both by intention to treat and per protocol. This trial is registered with ClinicalTrials.gov, number NCT00696969. FINDINGS: Between June, 2008, and July, 2009, 634 patients were assigned amphotericin B (n=157), liposomal amphotericin B with miltefosine (n=160) or paromomycin (n=158), or miltefosine and paromomycin (n=159). 618 patients were in the per-protocol population. There were two relapses in each group. The numbers with definitive cure at 6 months for the intention-to-treat population were 146 (cure rate 93·0%; CI 87·5-96·3) for amphotericin B, 156 (97·5%; 93·3-99·2) for liposomal amphotericin B and miltefosine, 154 (97·5%; 93·24-99·2) for liposomal amphotericin B and paromomycin, and 157 (98·7%; 95·1-99·8) for miltefosine and paromomycin. All combinations were non-inferior to the standard treatment, in both the intention-to-treat and per-protocol populations. Patients in the combination groups had fewer adverse events than did those assigned standard treatment. INTERPRETATION: Combination treatments for visceral leishmaniasis are efficacious and safe, and decrease the duration of therapy, thereby encouraging adherence and reducing emergence of drug-resistant parasites. FUNDING: Drugs for Neglected Diseases initiative and the Indian Council of Medical Research.


Subject(s)
Amphotericin B/administration & dosage , Antiprotozoal Agents/administration & dosage , Leishmaniasis, Visceral/drug therapy , Paromomycin/administration & dosage , Phosphorylcholine/analogs & derivatives , Adolescent , Adult , Amphotericin B/adverse effects , Antiprotozoal Agents/adverse effects , Child , Child, Preschool , Creatinine/analysis , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Female , Hemoglobins/analysis , Humans , India , Liver/enzymology , Liver Function Tests , Male , Middle Aged , Paromomycin/adverse effects , Phosphorylcholine/administration & dosage , Phosphorylcholine/adverse effects , Recurrence , Young Adult
11.
Trans R Soc Trop Med Hyg ; 105(2): 115-7, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21129762

ABSTRACT

The combination of one intravenous administration of 5mg/kg Ambisome and oral administration of miltefosine, 2.5mg/kg/day for 14 days, was evaluated in 135 Indian patients with kala-azar. The Intent-to-Treat cure rate at 6 months was 124 of the 135 enrolled patients (91.9%: 95% CI = 86-96%), and the per protocol cure rate was 124 of 127 evaluable patients (97.6%: 95% CI = 93-100%). Side effects could be attributed to each drug separately: fevers, rigors and back pain due to Ambisome; gastrointestinal side effects due to miltefosine. This combination is attractive for reasons of efficacy, tolerance, and feasibility of administration, although the gastrointestinal side effects of miltefosine require medical vigilance. Clinical Trials.gov identification number: NCT00371995.


Subject(s)
Amphotericin B/administration & dosage , Antiprotozoal Agents/administration & dosage , Leishmaniasis, Visceral/drug therapy , Phosphorylcholine/analogs & derivatives , Administration, Oral , Adolescent , Adult , Aged , Antiprotozoal Agents/adverse effects , Child , Child, Preschool , Drug Therapy, Combination/methods , Female , Gastrointestinal Diseases/chemically induced , Humans , Infusions, Intravenous , Leishmaniasis, Visceral/complications , Male , Middle Aged , Phosphorylcholine/administration & dosage , Phosphorylcholine/adverse effects , Treatment Outcome , Young Adult
12.
Ann Card Anaesth ; 13(2): 154-8, 2010.
Article in English | MEDLINE | ID: mdl-20442547

ABSTRACT

Ebstein's anomaly (EA) is the most common cause of congenital tricuspid regurgitation. The associated anomalies commonly seen are atrial septal defect or patent foramen ovale and accessory conduction pathways. Its association with coexisting mitral stenosis (MS) has uncommonly been described. The hemodynamic consequences and anesthetic implications, of a combination of EA and rheumatic MS, have not so far been discussed in the literature. We report successful anesthetic management of a repair of EA and mitral valve replacement in a patient with coexisting Wolff-Parkinson-White (WPW) syndrome.


Subject(s)
Anesthesia, General/methods , Ebstein Anomaly/surgery , Mitral Valve Stenosis/surgery , Wolff-Parkinson-White Syndrome/complications , Cardiopulmonary Bypass/methods , Ebstein Anomaly/complications , Female , Humans , Mitral Valve Stenosis/complications , Treatment Outcome , Young Adult
16.
Asian Cardiovasc Thorac Ann ; 17(4): 419-21, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19713343

ABSTRACT

A 34-year old woman with rheumatic mitral stenosis was found to have complete dual inferior venae cavae with bilateral infrarenal and suprarenal segments, on balloon mitral valvuloplasty. The bilateral, renal, and gonadal veins drained separately on the ipsilateral side. The left inferior vena cava was larger than the right, and the right inferior vena cava had an aneurysmal dilatation near its origin. The left inferior vena cava drained into the superior vena cava-right atrial junction.


Subject(s)
Aneurysm/complications , Mitral Valve Stenosis/complications , Rheumatic Heart Disease/complications , Vascular Malformations/complications , Vena Cava, Inferior/abnormalities , Adult , Aneurysm/diagnostic imaging , Catheterization , Female , Humans , Incidental Findings , Mitral Valve Stenosis/therapy , Phlebography/methods , Rheumatic Heart Disease/therapy , Tomography, X-Ray Computed , Vascular Malformations/diagnostic imaging , Vena Cava, Inferior/diagnostic imaging
18.
Ther Clin Risk Manag ; 5(1): 117-24, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19436614

ABSTRACT

BACKGROUND: There is significant variation in Amphotericin B (AMB) efficacy and relapses in antimony unresponsive visceral leishmaniasis (VL) cases over a period of time (10-15 years). Keeping in mind the above mentioned view this study was undertaken with an objective to assess the magnitude of cure and relapse rates of AMB in the treatment of antimony unresponsive VL cases. METHODS: In a controlled, randomized nonblinded clinical trial, we evaluated the cure and relapse rate of Amphotericin B deoxycholate as compared to pentamidine. A total of 82 sodium stibogluconate (SSG) unresponsive and parasitologically confirmed VL cases were included in this study and randomized into two groups, test (Amphotericin B) and control (Pentamidine). Both the groups were treated with recommended dosages (as per World Health Organization guidelines) of respective medicines. All the patients were followed up on 1st, 2nd, and 6th month after end of treatment. RESULTS: Apparent cure rate in the Amphotericin B group was found to be 95% (39/41) compared with 83% (34/41) in the Pentamidine group, which shows significant statistical difference (p = 0.05). The ultimate cure rate was found 92% (38/41) in the Amphotericin B group compared to 73% (30/41) in the Pentamidine group, which shows a significant statistical difference (Yates corrected chi-square = 4.42, p = 0.04). Similarly, significant statistical difference was observed in the relapse rate of the Amphotericin group compared to the Pentamidine group (p = 0.03). CONCLUSIONS: AMB may still be the drug of choice in the management of resistant VL cases in Bihar, India. This is due to its consistent apparent cure rate (95%), low relapse rate (2.5%), and cost effectiveness compared with other available antileishmanial drugs. It is a safe drug even in case of pregnancy. Efforts should be taken to form a future strategy so that this drug and coming newer drugs do not meet a similar fate as has happened to SSG and pentamidine over a span of 10-15 years.

SELECTION OF CITATIONS
SEARCH DETAIL
...